NeoReactomicsReactomics in Newborn Screening
The patented technology enables the measurement of multiple enzymatic activities from a single dried blood spot punch, expanding the scope of reactomics.
With straightforward sample preparation and a fluorescence-based readout, this platform has the potential to support scalable functional assays for newborn screening, including both first-tier and second-tier testing.
During 2025 and 2026, we have been working to validate our technology through the MetabPlus program, focusing on a panel of 83 enzymes selected according to clinical criteria, including their association with severe pediatric disorders for which effective treatments are available.
The program combines experimental studies with neonatal and adult data to assess the platform’s analytical performance.
MetabPlus is a public–private collaboration between IBIMA Plataforma BIONAND and Reactomix, S.L., with participation from CSIC, the IBIMA Chemistry Platform, and the Eastern Andalusia Newborn Screening Laboratory at Hospital Materno Infantil de Málaga.
The program receives public funding from the Spanish Ministry of Science and the European Union.
Advancing towards a functional approach to complement metabolic and genomic newborn screening.
Designed to measure the activity of 83 enzymes selected for clinical relevance, using a single dried blood spot (DBS) punch and fluorescence detection.
In the liquid format, the complete workflow takes approximately 4 hours per plate, including a 90-minute incubation.
Multiplex Enzymatic Profiling from Dried Blood Spot: Validation of a Scalable Reactomics Platform
Dr Raquel Yahyaoui, Principal Investigator of the MetabPlus programme, presented promising results from our ongoing validation work at the 2026 APHL Newborn Screening Symposium.
Detailed results are not publicly available at this stage.
Measuring multiple enzyme activities in a single assay.
Providing functional evidence to help interpret metabolic or genomic findings.
Continuing the MetabPlus program.
Evaluating the assay using dried blood spot (DBS) samples from children with confirmed diagnoses.
Planned analysis of 50,000 newborn samples, with comparison against next-generation sequencing (NGS) results.
Evaluating how well the test identifies affected newborns, how it fits into routine screening, and how much it costs per sample.
We would be pleased to share our research progress, discuss your questions and explore opportunities for collaboration.
Scientific Coordinator & Clinical Lead
Laboratory Scientific Lead
Liquid-format Lead
Solid-format Lead
Bioinformatics Lead
CEO, Reactomix S.L.
Collaborators
Manuel Ferrer — CSIC
José Juan Reina & team — IBIMA Chemistry Platform
contact@neoreactomics.com
The form is ready, but sending has not been activated yet. No information has been saved or sent.